An Open-Label, Single-Arm Phase II Study of RAD001 in Patients with Mantle Cell Lymphoma who are Refractory or Intolerant to Velcade (Bortezomib).

Trial Profile

An Open-Label, Single-Arm Phase II Study of RAD001 in Patients with Mantle Cell Lymphoma who are Refractory or Intolerant to Velcade (Bortezomib).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2014

At a glance

  • Drugs Everolimus (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms PILLAR-1
  • Most Recent Events

    • 02 Aug 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov record.
    • 01 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Mar 2012 Planned end date changed from 1 Mar 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top